Le Dieu Rifca, Gribben John
Institute of Cancer, CRUK Medical Oncology Unit, Barts and The London School of Medicine, Queen Mary, University of London, London, UK.
Semin Oncol. 2006 Apr;33(2):220-9. doi: 10.1053/j.seminoncol.2005.12.012.
B-cell chronic lymphocytic leukemia (CLL) would appear to be an ideal target of T-cell-mediated responses against the cancer cell. The cancer arises in cells that can act as antigen-presenting cells (APCs), CLL cells express tumor antigens, and the cells can be a target of the allogeneic T cells in a graft-versus-leukemia effect. Despite these potential benefits, immune responses against CLL cells have been difficult to elicit. CLL induces immune defects in the host, the tumor cells are inefficient APCs, and therapies given to patients with CLL are themselves immunosuppressive. Successful vaccination approaches in this disease will require steps to overcome these difficulties, including steps to improve the immune defects in this disease, identification of the targets of the immune response to monitor immunologic responses, and improved presentation of antigen.
B细胞慢性淋巴细胞白血病（CLL）似乎是T细胞介导的针对癌细胞反应的理想靶点。这种癌症起源于可作为抗原呈递细胞（APC）的细胞，CLL细胞表达肿瘤抗原，并且这些细胞在移植物抗白血病效应中可以成为同种异体T细胞的靶点。尽管有这些潜在益处，但针对CLL细胞的免疫反应却难以引发。CLL会在宿主中诱导免疫缺陷，肿瘤细胞是低效的APC，并且给予CLL患者的治疗本身具有免疫抑制作用。针对这种疾病的成功疫苗接种方法将需要采取措施来克服这些困难，包括改善该疾病免疫缺陷的措施、识别免疫反应靶点以监测免疫反应，以及改进抗原呈递。
